A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Cresemba to Evaluate Safety and Effectiveness in Patients With Invasive Aspergillosis or Invasive Mucormycosis in Korea
Latest Information Update: 15 Mar 2023
At a glance
- Drugs Isavuconazonium (Primary)
- Indications Aspergillosis; Zygomycosis
- Focus Adverse reactions
- Sponsors Pfizer
- 20 May 2021 Planned initiation date changed from 31 Jan 2021 to 30 Jun 2021.
- 20 May 2021 Status changed from not yet recruiting to recruiting.
- 12 Feb 2021 New trial record